Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative

Tetanus is a vaccine-preventable disease that yearly causes a total of 309,000 deaths. Of particular concern is maternal and neonatal tetanus (MNT), which can be prevented through immunization of the mother in pregnancy. In 2000, neonatal tetanus alone was responsible for an estimated 200,000 deaths...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2003-07, Vol.21 (24), p.3442-3445
Hauptverfasser: Vandelaer, J., Birmingham, M., Gasse, F., Kurian, M., Shaw, C., Garnier, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3445
container_issue 24
container_start_page 3442
container_title Vaccine
container_volume 21
creator Vandelaer, J.
Birmingham, M.
Gasse, F.
Kurian, M.
Shaw, C.
Garnier, S.
description Tetanus is a vaccine-preventable disease that yearly causes a total of 309,000 deaths. Of particular concern is maternal and neonatal tetanus (MNT), which can be prevented through immunization of the mother in pregnancy. In 2000, neonatal tetanus alone was responsible for an estimated 200,000 deaths. While the focus is on 57 priority countries, 90% of the neonatal tetanus deaths occur in 27 countries. UNICEF is spearheading the effort to eliminate MNT by the year 2005, with the support of numerous partners. MNT elimination is defined as less than one case of neonatal tetanus per 1000 live births at district level. The main strategies consist of promotion of clean delivery practices, immunization of women with a tetanus toxoid (TT) containing vaccine, and surveillance. Maternal tetanus immunization is, in most developing countries, implemented as part of the routine immunization program. However, large areas remain underserved, due to logistical, cultural, economical or other reasons. In order to achieve the target of MNT elimination by 2005, and to offer protection to women and children otherwise deprived from regular immunization services, countries are encouraged to adopt the “high risk approach”. This approach implies that, in addition to routine immunization of pregnant women, all women of child bearing age living in high risk areas are targeted for immunization with three doses of a tetanus toxoid containing vaccine (TT or Td), implemented as “supplemental immunization activities” (SIAs). Through SIAs, about 17 million women have been reached with at least two doses of TT vaccine in the past 3 years, and it is estimated that another 200 million need to be targeted in the years to come. SIAs should substantially reduce the burden of disease. Countries will also have to improve their existing immunization and clean delivery programs to ensure that the elimination of maternal and neonatal tetanus is maintained.
doi_str_mv 10.1016/S0264-410X(03)00347-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73445823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03003475</els_id><sourcerecordid>73445823</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-e51f3a26fd81ae97fa02a898eeac338d1e3b2be3b6531dc1f0255d31ca8a2e463</originalsourceid><addsrcrecordid>eNqFkd9rFDEQx4NY7LX6JygBUfRhNT822awvIqXaQqsPVvAtzCWzmrKXPZPsgf99c73TQl_6kplMPvMlM19CnnP2jjOu339nQrdNy9nPN0y-ZUy2XaMekQU3nWyE4uYxWfxHDslRzteMMSV5_4QccmEUk0ovyHCFBeKcaYjU4wbHaR3iL-qmOZYUMH-gEOm89lCQTpGW30gva54ijPXF0684RSj18k_ndAyrUEuh0ucxlFDTDT4lBwOMGZ_t4zH58fn06uSsufj25fzk00XjFNelQcUHCUIP3nDAvhuACTC9QQQnpfEc5VIs66HrIN7xgQmlvOQODAhstTwmr3e66zT9mTEXuwrZ4ThCxGnOtpNtq4yQD4LcGCbqhir48h54Pc3b8SujWq11p-WWUjvKpSnnhINdp7CC9NdyZrd-2Vu_7NYMy6S99cuq2vdirz4vV-jvuvYGVeDVHoDsYBwSRBfyHdf2fV_FKvdxx2Hd7iZgstkFjA59SOiK9VN44Cs3oiGyWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1546667636</pqid></control><display><type>article</type><title>Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Vandelaer, J. ; Birmingham, M. ; Gasse, F. ; Kurian, M. ; Shaw, C. ; Garnier, S.</creator><creatorcontrib>Vandelaer, J. ; Birmingham, M. ; Gasse, F. ; Kurian, M. ; Shaw, C. ; Garnier, S.</creatorcontrib><description>Tetanus is a vaccine-preventable disease that yearly causes a total of 309,000 deaths. Of particular concern is maternal and neonatal tetanus (MNT), which can be prevented through immunization of the mother in pregnancy. In 2000, neonatal tetanus alone was responsible for an estimated 200,000 deaths. While the focus is on 57 priority countries, 90% of the neonatal tetanus deaths occur in 27 countries. UNICEF is spearheading the effort to eliminate MNT by the year 2005, with the support of numerous partners. MNT elimination is defined as less than one case of neonatal tetanus per 1000 live births at district level. The main strategies consist of promotion of clean delivery practices, immunization of women with a tetanus toxoid (TT) containing vaccine, and surveillance. Maternal tetanus immunization is, in most developing countries, implemented as part of the routine immunization program. However, large areas remain underserved, due to logistical, cultural, economical or other reasons. In order to achieve the target of MNT elimination by 2005, and to offer protection to women and children otherwise deprived from regular immunization services, countries are encouraged to adopt the “high risk approach”. This approach implies that, in addition to routine immunization of pregnant women, all women of child bearing age living in high risk areas are targeted for immunization with three doses of a tetanus toxoid containing vaccine (TT or Td), implemented as “supplemental immunization activities” (SIAs). Through SIAs, about 17 million women have been reached with at least two doses of TT vaccine in the past 3 years, and it is estimated that another 200 million need to be targeted in the years to come. SIAs should substantially reduce the burden of disease. Countries will also have to improve their existing immunization and clean delivery programs to ensure that the elimination of maternal and neonatal tetanus is maintained.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(03)00347-5</identifier><identifier>PMID: 12850356</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Bacterial diseases ; Bacterial diseases of the nervous system. Bacterial myositis ; Biological and medical sciences ; Births ; Clean deliveries ; Developing Countries ; Diphtheria ; Female ; Human bacterial diseases ; Humans ; Immunization ; Immunization Programs ; Infant ; Infant, Newborn - immunology ; Infectious diseases ; Initiatives ; LDCs ; Maternal and neonatal tetanus elimination ; Maternal immunization ; Medical sciences ; Mortality ; Pregnancy ; Supplemental immunization activities ; Surveillance ; Tetanus ; Tetanus - epidemiology ; Tetanus - prevention &amp; control ; Tropical medicine ; TT vaccine ; Vaccination ; Vaccines ; Womens health</subject><ispartof>Vaccine, 2003-07, Vol.21 (24), p.3442-3445</ispartof><rights>2003</rights><rights>2003 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jul 28, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-e51f3a26fd81ae97fa02a898eeac338d1e3b2be3b6531dc1f0255d31ca8a2e463</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1546667636?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14999003$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12850356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vandelaer, J.</creatorcontrib><creatorcontrib>Birmingham, M.</creatorcontrib><creatorcontrib>Gasse, F.</creatorcontrib><creatorcontrib>Kurian, M.</creatorcontrib><creatorcontrib>Shaw, C.</creatorcontrib><creatorcontrib>Garnier, S.</creatorcontrib><title>Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Tetanus is a vaccine-preventable disease that yearly causes a total of 309,000 deaths. Of particular concern is maternal and neonatal tetanus (MNT), which can be prevented through immunization of the mother in pregnancy. In 2000, neonatal tetanus alone was responsible for an estimated 200,000 deaths. While the focus is on 57 priority countries, 90% of the neonatal tetanus deaths occur in 27 countries. UNICEF is spearheading the effort to eliminate MNT by the year 2005, with the support of numerous partners. MNT elimination is defined as less than one case of neonatal tetanus per 1000 live births at district level. The main strategies consist of promotion of clean delivery practices, immunization of women with a tetanus toxoid (TT) containing vaccine, and surveillance. Maternal tetanus immunization is, in most developing countries, implemented as part of the routine immunization program. However, large areas remain underserved, due to logistical, cultural, economical or other reasons. In order to achieve the target of MNT elimination by 2005, and to offer protection to women and children otherwise deprived from regular immunization services, countries are encouraged to adopt the “high risk approach”. This approach implies that, in addition to routine immunization of pregnant women, all women of child bearing age living in high risk areas are targeted for immunization with three doses of a tetanus toxoid containing vaccine (TT or Td), implemented as “supplemental immunization activities” (SIAs). Through SIAs, about 17 million women have been reached with at least two doses of TT vaccine in the past 3 years, and it is estimated that another 200 million need to be targeted in the years to come. SIAs should substantially reduce the burden of disease. Countries will also have to improve their existing immunization and clean delivery programs to ensure that the elimination of maternal and neonatal tetanus is maintained.</description><subject>Adult</subject><subject>Bacterial diseases</subject><subject>Bacterial diseases of the nervous system. Bacterial myositis</subject><subject>Biological and medical sciences</subject><subject>Births</subject><subject>Clean deliveries</subject><subject>Developing Countries</subject><subject>Diphtheria</subject><subject>Female</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Programs</subject><subject>Infant</subject><subject>Infant, Newborn - immunology</subject><subject>Infectious diseases</subject><subject>Initiatives</subject><subject>LDCs</subject><subject>Maternal and neonatal tetanus elimination</subject><subject>Maternal immunization</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Pregnancy</subject><subject>Supplemental immunization activities</subject><subject>Surveillance</subject><subject>Tetanus</subject><subject>Tetanus - epidemiology</subject><subject>Tetanus - prevention &amp; control</subject><subject>Tropical medicine</subject><subject>TT vaccine</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Womens health</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkd9rFDEQx4NY7LX6JygBUfRhNT822awvIqXaQqsPVvAtzCWzmrKXPZPsgf99c73TQl_6kplMPvMlM19CnnP2jjOu339nQrdNy9nPN0y-ZUy2XaMekQU3nWyE4uYxWfxHDslRzteMMSV5_4QccmEUk0ovyHCFBeKcaYjU4wbHaR3iL-qmOZYUMH-gEOm89lCQTpGW30gva54ijPXF0684RSj18k_ndAyrUEuh0ucxlFDTDT4lBwOMGZ_t4zH58fn06uSsufj25fzk00XjFNelQcUHCUIP3nDAvhuACTC9QQQnpfEc5VIs66HrIN7xgQmlvOQODAhstTwmr3e66zT9mTEXuwrZ4ThCxGnOtpNtq4yQD4LcGCbqhir48h54Pc3b8SujWq11p-WWUjvKpSnnhINdp7CC9NdyZrd-2Vu_7NYMy6S99cuq2vdirz4vV-jvuvYGVeDVHoDsYBwSRBfyHdf2fV_FKvdxx2Hd7iZgstkFjA59SOiK9VN44Cs3oiGyWg</recordid><startdate>20030728</startdate><enddate>20030728</enddate><creator>Vandelaer, J.</creator><creator>Birmingham, M.</creator><creator>Gasse, F.</creator><creator>Kurian, M.</creator><creator>Shaw, C.</creator><creator>Garnier, S.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20030728</creationdate><title>Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative</title><author>Vandelaer, J. ; Birmingham, M. ; Gasse, F. ; Kurian, M. ; Shaw, C. ; Garnier, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-e51f3a26fd81ae97fa02a898eeac338d1e3b2be3b6531dc1f0255d31ca8a2e463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Bacterial diseases</topic><topic>Bacterial diseases of the nervous system. Bacterial myositis</topic><topic>Biological and medical sciences</topic><topic>Births</topic><topic>Clean deliveries</topic><topic>Developing Countries</topic><topic>Diphtheria</topic><topic>Female</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Programs</topic><topic>Infant</topic><topic>Infant, Newborn - immunology</topic><topic>Infectious diseases</topic><topic>Initiatives</topic><topic>LDCs</topic><topic>Maternal and neonatal tetanus elimination</topic><topic>Maternal immunization</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Pregnancy</topic><topic>Supplemental immunization activities</topic><topic>Surveillance</topic><topic>Tetanus</topic><topic>Tetanus - epidemiology</topic><topic>Tetanus - prevention &amp; control</topic><topic>Tropical medicine</topic><topic>TT vaccine</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vandelaer, J.</creatorcontrib><creatorcontrib>Birmingham, M.</creatorcontrib><creatorcontrib>Gasse, F.</creatorcontrib><creatorcontrib>Kurian, M.</creatorcontrib><creatorcontrib>Shaw, C.</creatorcontrib><creatorcontrib>Garnier, S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vandelaer, J.</au><au>Birmingham, M.</au><au>Gasse, F.</au><au>Kurian, M.</au><au>Shaw, C.</au><au>Garnier, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2003-07-28</date><risdate>2003</risdate><volume>21</volume><issue>24</issue><spage>3442</spage><epage>3445</epage><pages>3442-3445</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Tetanus is a vaccine-preventable disease that yearly causes a total of 309,000 deaths. Of particular concern is maternal and neonatal tetanus (MNT), which can be prevented through immunization of the mother in pregnancy. In 2000, neonatal tetanus alone was responsible for an estimated 200,000 deaths. While the focus is on 57 priority countries, 90% of the neonatal tetanus deaths occur in 27 countries. UNICEF is spearheading the effort to eliminate MNT by the year 2005, with the support of numerous partners. MNT elimination is defined as less than one case of neonatal tetanus per 1000 live births at district level. The main strategies consist of promotion of clean delivery practices, immunization of women with a tetanus toxoid (TT) containing vaccine, and surveillance. Maternal tetanus immunization is, in most developing countries, implemented as part of the routine immunization program. However, large areas remain underserved, due to logistical, cultural, economical or other reasons. In order to achieve the target of MNT elimination by 2005, and to offer protection to women and children otherwise deprived from regular immunization services, countries are encouraged to adopt the “high risk approach”. This approach implies that, in addition to routine immunization of pregnant women, all women of child bearing age living in high risk areas are targeted for immunization with three doses of a tetanus toxoid containing vaccine (TT or Td), implemented as “supplemental immunization activities” (SIAs). Through SIAs, about 17 million women have been reached with at least two doses of TT vaccine in the past 3 years, and it is estimated that another 200 million need to be targeted in the years to come. SIAs should substantially reduce the burden of disease. Countries will also have to improve their existing immunization and clean delivery programs to ensure that the elimination of maternal and neonatal tetanus is maintained.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>12850356</pmid><doi>10.1016/S0264-410X(03)00347-5</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2003-07, Vol.21 (24), p.3442-3445
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_73445823
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Adult
Bacterial diseases
Bacterial diseases of the nervous system. Bacterial myositis
Biological and medical sciences
Births
Clean deliveries
Developing Countries
Diphtheria
Female
Human bacterial diseases
Humans
Immunization
Immunization Programs
Infant
Infant, Newborn - immunology
Infectious diseases
Initiatives
LDCs
Maternal and neonatal tetanus elimination
Maternal immunization
Medical sciences
Mortality
Pregnancy
Supplemental immunization activities
Surveillance
Tetanus
Tetanus - epidemiology
Tetanus - prevention & control
Tropical medicine
TT vaccine
Vaccination
Vaccines
Womens health
title Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T23%3A35%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tetanus%20in%20developing%20countries:%20an%20update%20on%20the%20Maternal%20and%20Neonatal%20Tetanus%20Elimination%20Initiative&rft.jtitle=Vaccine&rft.au=Vandelaer,%20J.&rft.date=2003-07-28&rft.volume=21&rft.issue=24&rft.spage=3442&rft.epage=3445&rft.pages=3442-3445&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(03)00347-5&rft_dat=%3Cproquest_cross%3E73445823%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1546667636&rft_id=info:pmid/12850356&rft_els_id=S0264410X03003475&rfr_iscdi=true